Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Trade names | Corbevax |
Other names | BECOV2D, Biological E COVID-19 |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
Corbevax is a protein subunit COVID-19 vaccine[1][2][3][4] developed by Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas and Dynavax technologies based in Emeryville, California.[5][6] It is licensed to Indian biopharmaceutical firm Biological E. Limited (BioE) for development and production.[7][8]